W. D. Tolbert

Piperidine CD4-mimetic compounds expose vulnerable Env epitopes sensitizing HIV-1-infected cells to ADCC

The paper describes piperidine-based CD4-mimetic compounds that expose HIV-1 Env epitopes, increasing sensitivity to ADCC by targeting Asp368.

Molecular basis for antiviral activity of pediatric neutralizing antibodies targeting SARS-CoV-2 Spike receptor binding domain

This study identifies two potent neutralizing antibodies, EH3 and EH8, from a pediatric patient that cross-neutralize SARS-CoV-2 variants and provide in vivo protection against the Delta VOC.

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities

The paper develops ACE2-Fc molecules that neutralize SARS-CoV-2 and show Fc-effector activity, effectively treating lethal infection in mice.

Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological and pathological disease in a Syrian hamster model of COVID-19

This study shows that nebulized NIH-CoVnb-112 nanobody reduces weight loss, viral burden, and lung pathology in Syrian hamsters infected with SARS-CoV-2.

An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice

Across functional boundaries: making non-neutralizing antibodies to neutralize HIV-1 and mediate Fc-mediated effector killing of infected cells

This paper designs Ab-CD4 chimeric proteins that open HIV-1 Env trimers to expose non-neutralizing epitopes, enabling both neutralization and ADCC against HIV-1.

Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern

This study characterizes two SARS-CoV-2 antibodies effective against variants, showing their structural basis and mechanisms of neutralization.

Boosting with ALVAC-HIV and AIDSVAX B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity

The paper shows that boosting RV144 vaccine recipients with ALVAC-HIV and AIDSVAX B/E increases C1C2-specific antibody-dependent cellular cytotoxicity breadth and potency.